Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Carol Aghajanian"'
Autor:
Beryl L. Manning‐Geist, Ryan M. Kahn, David Nemirovsky, Jeffrey Girshman, Anya Laibangyang, Sushmita Gordhandas, Alexia Iasonos, M. Herman Chui, Kara Long Roche, Oliver Zivanovic, Dennis S. Chi, Carol Aghajanian, Rachel N. Grisham
Publikováno v:
Cancer.
Autor:
Helen Won, Carol Aghajanian, Catherine Zimel, Paul Sabbatini, Martee L. Hensley, Roisin E. O'Cearbhaill, Krysten Soldan, William P. Tew, Kenneth Seier, Rachel N. Grisham, Maria M. Rubinstein, Vicky Makker, S. Duygu Selcuklu, David M. Hyman, Joyce Guillen, Tiffany A. Troso-Sandoval, Imogen Caird, Alexia Iasonos, Jean Torrisi
Publikováno v:
Cancer
Background PI3K pathway activation is common in endometrial cancer. We evaluated the safety and efficacy of the dual PI3K/mTOR inhibitor, LY3023414, in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Meth
Autor:
Carol Aghajanian, Yulei Wang, Jill M. Spoerke, Shan Lu, Ling-Yuh Huw, Ursula A. Matulonis, Rui Zhu, Vicky Makker, Houston Gilbert, Hema Parmar, Ling Ma, Fernando O. Recio, Mark R. Lackner, Joseph A. Ware, Jennifer O. Lauchle, Hartmut Koeppen
Publikováno v:
Cancer. 122:3519-3528
BACKGROUND The current single-arm, open-label trial was designed to evaluate the activity of apitolisib (GDC-0980), a dual phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor, in patients with advanced endometrial cancer (EC
Autor:
Karuna Garg, Alexia Iasonos, Fanny Dao, Douglas A. Levine, Rachel N. Grisham, David M. Hyman, David R. Spriggs, Michael F. Berger, Deborah DeLair, David B. Solit, Qin Zhou, Carol Aghajanian, Gopa Iyer
Publikováno v:
Cancer. 119:548-554
BACKGROUND: Low-grade serous (LGS) ovarian cancer is a chemoresistant disease that accounts for 10% of serous ovarian cancers. Prior studies have reported that 28% to 35% of serous borderline (SB)/LGS ovarian tumors harbor a BRAF mutation, suggesting
Autor:
David R. Spriggs, Richard R. Barakat, Noah D. Kauff, Jasmine Bhatia, David M. Hyman, Qin Zhou, Carol Aghajanian, M. Phillips, Rachel N. Grisham, Kenneth Offit, Angela G. Arnold, Alexia Iasonos, Douglas A. Levine
Publikováno v:
Cancer. 118:3703-3709
BACKGROUND Multiple observational studies have suggested that BRCA-associated ovarian cancers have improved survival compared to BRCA-negative ovarian cancers. Most of these studies, however, have combined BRCA1 and BRCA2 patients or evaluated only B
Autor:
Martee L. Hensley, Felicia Derosa, Kay J. Park, Jason A. Konner, Paul Sabbatini, David R. Spriggs, Carol Aghajanian, Alexia Iasonos, Douglas A. Levine, Margrit M. Juretzka, Sharyn N. Lewin, Julie Esch
Publikováno v:
Cancer. 110:2458-2466
BACKGROUND. The current study was conducted to determine the effect of goserelin and bicalutamide on progression-free survival (PFS) in patients with epithelial ovarian cancer who were in second or greater complete disease remission. METHODS. Patient
Autor:
Christin Whalen, Alexia Iasonos, Martee L. Hensley, Corinne Zarwan, L. Pereira, Paul Sabbatini, Suzanne Berlin, William P. Tew, Carol Aghajanian, Sara Kravetz, Xiaoyu Jia
Publikováno v:
Cancer. 118(9)
BACKGROUND: Eribulin mesylate is a tubulin inhibitor with activity superior to paclitaxel in NIH:OVCAR-3 human epithelial ovarian cancer xenograft models. In this study, the authors assessed the efficacy of eribulin in platinum-resistant and platinum
Autor:
Paul Sabbatini, Douglas A. Levine, Carol L. Brown, Jason A. Konner, Carol Aghajanian, Oliver Zivanovic, Richard R. Barakat, Nadeem R. Abu-Rustum
Publikováno v:
Cancer. 112(12)
BACKGROUND. The aim was to determine the long-term outcome for patients with FIGO stage IV epithelial ovarian carcinoma (EOC) treated with intraperitoneal (IP) chemotherapy after second-look assessment. METHODS. By using data from a retrospective coh
Autor:
Cyrus V. Hedvat, Alexia Iasonos, Lynn Bonham, Catherine Diefenbach, Jack W. Singer, Jakob Dupont, Carol Aghajanian, Robert A. Soslow, Irina Linkov, Richard R. Barakat
Publikováno v:
Cancer. 107(7)
BACKGROUND Lysophosphatidic acid acyltransferase-β (LPAAT-β) tumor expression is an emerging prognostic, diagnostic, and therapeutic target in early epithelial ovarian cancer (EOC). The significance of tumor overexpression of LPAAT-β was investiga
Autor:
Sarah Schwabenbauer, John P. Diaz, Richard Barakat, Jae Huh, Ennapadam Venkatraman, Amanda J. Hummer, Kristina McCaughty, Carol Aghajanian, Dennis S. Chi, Nadeem R. Abu-Rustum, Yukio Sonoda
Publikováno v:
Cancer. 106(9)
The benefit of cytoreductive surgery for patients with recurrent epithelial ovarian cancer has not been defined clearly. The objective of this study was to identify prognostic factors for survival in patients who underwent secondary cytoreduction for